IFNG and multidrug-resistant tuberculosis: IFN-γ: In clinical trials for pulmonary MDR-TB, recombinant IFN-γ has been shown to activate macrophages, enhancing their ability to phagocytose and kill Mtb, thereby improving sputum conversion rates and reducing lung pathology.